Rua Half-Year Result – Constructive Period with First Product, First Revenue Imminent
Rua Half-Year Result – Constructive Period with First Product, First Revenue Imminent. Rua Bioscience Limited (NZX: RUA) has today announced its financial results for the six months to 31 December 2021.
The loss after tax for the six months to 31 December 2021 was $2.46m, with total cash and investments on hand at the end of the period of $12.29m.
Pharmaceutical Giant Acquires German Distributor Nimbus Health
Rua Bioscience is pleased to share the news that multi-national pharmaceutical company Dr Reddy's Laboratories Ltd today announced it has entered into a definitive agreement to acquire Nimbus Health. Rua Bioscience was the first New Zealand company to announce a binding export agreement with the reputable distributor in Germany and is Nimbus Health's exclusive New Zealand supplier of medicinal cannabis products.
Rua’s Australian Supplier, Cann Group, Receives GMP Certification for Southern Facility
Rua Bioscience is pleased to share that Cann Group has been granted a GMP licence to manufacture therapeutic goods for its Southern facility (Southern GMP Licence) by Australia’s Therapeutic Goods Administration (TGA).
Shareholders Approve Zalm Therapeutics Share Issue – Set Stage to Accelerate Market Entry and Expand Patient Choice
Rua Bioscience shareholders have overwhelmingly approved the purchase of Zalm, throwing further shareholder weight behind the company’s bid to become New Zealand’s premier medicinal cannabis company.